5-Methyl-2-phenyl-1,2-dihydropyrazol-3-one CAS 89-25-8

Product Description:

Product Name: 5-Methyl-2-phenyl-1,2-dihydropyrazol-3-one CAS NO: 89-25-8

Synonyms:

3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-;

3-methyl-1-phenyl-1H-pyrazol-5(4H)-one;

2,4-dihydro-5-methyl-2-phenyl-3h-pyrazol-3-one;

Chemical & Physical Properties:

Appearance: Light yellow crystalline powder

Assay :≥99.00%

Density: 1.12

Boiling Point: 287℃ (265 mmHg)

Melting Point: 127-131℃

Flash Point: 155.2℃

Water Solubility: 3 g/L (20℃)

Stability: Stable under normal temperatures and pressures

Storage Condition: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store protected from light.

Safety Information:

RTECS: UQ9625000

Safety Statements: S26-S36

HS Code: 2933199090

WGK Germany: 1

Risk Statements: R36/37/38

Hazard Code: Xi

Edaravone was marketed in Japan for improving neurologic recovery following acute brain infarction. Currently, several agents classified as neuroprotectants and acting by diverse mechanisms (inhibition of glutamate release, blockade of calcium channels, lazaroids) have been marketed for treating the outcomes of brain damage due to trauma, ischemia or cardiac arrest. Edavarone is the first antioxidant with free radical scavenging activity to be introduced for this pathology. This previously described molecule (in particular as norantipyrine, one of three metabolites of antipyrine in mammals) can be simply prepared by direct cyclization of phenylhydrazine with alkylacetoacetate. Edarevone is a lipophilic agent, readily accessible to brain tissue, that is capable of reducing edema in the brain following ischemia by blocking the arachidonic acid cascade triggering peroxidative neurodegeneration. Interestingly, this agent has been shown to quench active oxygen species in endothelial cell homogenate, as well as inhibiting in vitro lipid peroxidative disintegration of membranes, so making this compound effective during reperfusion following ischemic injury. As an additional indication, phase III trials started with edaravone for increasing the chance of recovery after subarachnoid hemorrhage.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.